Keeping track of new clinical trial opportunities across the United States can be a challenge, especially with many studies actively enrolling patients. This report summarizes the trials that have opened or started recruiting for adult and pediatric patients with a primary brain tumor between November 2024 and June 2025 (since our last report). Individuals are encouraged to follow the hyperlinks for each study to learn more and contact the responsible party for enrollment.
For a comprehensive list of ALL open brain tumor clinical trials, visit the NBTS Clinical Trial Finder, where you can search for potential opportunities for enrollment based on criteria specific to you.
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
This phase I trial is to assess whether the drugs ABBV-637 and ABBV-155 are safe treatments that cause few or mild side effects when given alone or in combination with ERAS-801 in people with recurrent GBM.
Dendritic Cell Immunotherapy for Treatment of Adult GBM
The goal of this phase II clinical trial is to learn if DOC1021 dendritic cell immunotherapy + pIFN alongside standard of care (SOC) will improve survival in adult patients newly diagnosed with glioblastoma (IDH-wt). It will also evaluate the safety of DOC1021 + pIFN. Researchers will compare DOC1021 added to SOC compared to SOC treatment alone.
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
This phase I trial studies how well zirconium (Zr)-89 crefmirlimab berdoxam and immuno-positron emission tomography (PET) identifies areas of immune cell activity in patients with brain tumors that can be removed by surgery (resectable).
ASCENT Intervention for Brain Tumor Patients
This study will examine the feasibility and acceptability of a novel, population-specific intervention designed to help patients with newly diagnosed malignant brain tumors cope with their illness.
Post-Operative Dosing of Dexamethasone in Patients with Brain Tumors After a Craniotomy, PODS Trial
This phase II trial tests the effect of decreasing (tapering) doses of dexamethasone on steroid side effects in patients after surgery to remove (craniotomy) a brain tumor.
Virtual Home-based Exercise Intervention (RISE) to Improve Cancer-Related Cognitive Impairment and Gut Microbiome in Adolescent and Young Adult Brain Tumor Survivors
This clinical trial evaluates the impact of a research intervention of virtually supervised exercise program (RISE) on cancer-related cognitive impairment (CRCI) and physical activity in adolescent and young adult (AYA) brain tumor survivors.
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
This is an open-label, randomized window-of-opportunity study of Troriluzole in participants with surgically accessible, recurrent isocitrate dehydrogenase wild-type (IDH WT) glioblastoma (GBM). Surgical window-of-opportunity clinical trials test how active the investigational drug is on tumors.
Atovaquone Combined With Radiation in Children With Malignant Brain Tumors (AflacBT2303)
This phase I trial is to assess the safety and tolerability of atovaquone in combination with standard radiation therapy (RT) for the treatment of pediatric patients with newly diagnosed pediatric high-grade glioma/diffuse midline glioma/diffuse intrinsic pontine glioma (pHGG/DMG/DIPG). The secondary aim is to assess the safety and tolerability of longer-term atovaquone treatment for pediatric patients with relapsed or progressed pHGG/DMG/DIPG and medulloblastoma (MB) or pHGG/DMG/DIPG after completion of RT and before progression.
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
This is a phase I/II multi-center, open label study in solid tumor patients – including certain patients with brain tumors – who have a confirmed MTAP loss in their tumor. The phase I portion is a dose escalation study of oral TNG456 administered as a single agent and in combination with oral abemaciclib in solid tumor patients with confirmed MTAP loss. In the phase II expansion part of the study, 6 arms defined by confirmed tumor types will enroll in parallel at the RP2D(s) of TNG456 and in combination. In both parts of the study participants who tolerate the drug may continue treatment until disease progression.
Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells
This phase I trial will assess the safety, tolerability, and early effectiveness of an experimental immunotherapy in children and young adults with recurrent, progressive, or refractory brain tumors.
RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)
This is a phase I study to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in adult patients with recurrent glioblastoma.
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
A phase I/II clinical trial to determine the strength of cobolimab and dostarlimab that is most tolerated in children and young adults who have advanced solid tumors, including many pediatric brain tumor types. This study also aims: (a) to check if it is safe to use cobolimab and dostarlimab combination in children and young adults, (b) to see how to manage the side effects that may occur, and (c) the effect of this treatment in participants.
Evaluation of 18F-Fluciclovine Positron Emission Tomography – Magnetic Resonance Imaging (PET-MRI) in LGG
The purpose of this phase I study is to see if 18F-Fluciclovine (Axumin®) is useful and safe in the management of children with low-grade glioma (LGG).
Study of Olutasidenib and Temozolomide in High-grade Glioma
The goal of this phase II study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to answer is whether the combination of olutasidenib and temozolomide (TMZ) can prolong the life of patients diagnosed with an IDH-mutant HGG.
Window of Opportunity Study of DSP-0390 in Gliomas
This study focuses on determining the pharmacokinetic and pharmacodynamic effect of DSP-0390 in brain and blood from patients with IDH-mutant WHO grade II or III glioma undergoing tumor resection.
Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
This phase I clinical study evaluates a single dose of 186RNL (radionuclide clinical study drug) administered through a convection enhanced delivery catheter (CED catheter) in participants who have already received a prior treatment of 186RNL.
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
This phase I trial tests the safety, side effects and best dose of TGFβR2KO/IL13Rα2 chimeric antigen receptor (CAR) T-cells given within the skull (intracranial) in treating patients with glioblastoma or IDH-mutant grade 3 or 4 astrocytoma that has come back after a period of improvement (recurrent) or that is growing, spreading, or getting worse (progressive). CAR T-cell therapy is a type of treatment in which a patient’s T cells (a type of immune system cell) are changed in the laboratory so they will attack tumor cells.
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High-Grade Glioma
This phase I/II study is designed to evaluate whether treatment with DB107-RRV (formerly Toca 511) in combination with DB107-FC (formerly Toca FC) when added to standard of care provides clinical benefit to newly diagnosed patients with newly diagnosed high-grade glioma when compared to historical performance previously determined in well controlled clinical trials published in the peer reviewed literature. This study is going to be conducted in newly diagnosed HGG patients receiving maximum surgical resection followed by radiation and temozolomide treatment.
Clinical Trial of BMS-986504 in Recurrent GBM Patients
This is a phase 0/I dose-escalation trial designed to evaluate the pharmacokinetics (PK) and safety and tolerability of the drug BMS-986504 (MRTX1719) in patients with recurrent glioblastoma (rGBM) with confirmed MTAP loss/deletion in their archival or pretreatment biopsy tissue, who are scheduled for surgical resection.
Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic Efficacy In Glioblastoma (GBM)
The goal of this phase II study is to evaluate the prognostic capacity of DMI (an advanced type of medical imaging) in a trial assessing the efficacy of adding BPM31510, a lipid nano dispersion of CoQ10, to standard treatment of glioblastoma (GBM).
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma (EF-41)
This is a phase III clinical trial of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the study is to evaluate the Overall Survival (OS).
D2C7-IT + 2141-V11 Combination Post-resection in rGBM
The purpose of this phase I study is to assess the safety and efficacy of the combination of the treatment D2C7-IT+2141-V11 administered in the non-enhancing tumor of patients with resected recurrent glioblastoma (rGBM) via convection enhanced delivery (CED), followed by subcutaneous cervical perilymphatic injections (CPLIs) of 2141-V11 2 and 4 weeks post infusion, then every 3 weeks for a year, and every 4-6 weeks thereafter if patients benefit from therapy.
OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial (OPTIMUS PRIME)
A phase II trial evaluating the safety and feasibility of the triple combination (TTFields, MLA, pembrolizumab) in adult patients diagnosed with recurrent or progressive glioblastoma (GBM) WHO Grade IV, IDH wild type or recurrent or progressive astrocytoma WHO grade IV.
Anti-GD2 ADC M3554 in Advanced Solid Tumors
The purpose of this phase I study is to establish the recommended doses and to further evaluate the safety and preliminary anti-tumor activity of the drug M3554 in participants with glioblastoma, IDH-wildtype.
PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial (POPCORN)
The purpose of this research study is to evaluate whether a specific type of radiation therapy, called “proton pulsed reduced dose rate” or “PRDR radiotherapy” has benefits at various dose levels and number of fractions in patients with recurrent high-grade glioma.
Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma
The objective of this phase I/II study is to determine the safety and tolerability of vorasidenib (Voranigo) in combination with temozolomide (TMZ) and to establish the recommended combination dose (RCD) of vorasidenib.
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
This is a phase I/II study evaluating the toxicity and early efficacy of dabrafenib and/or trametinib combined with nivolumab for the treatment of BRAF-altered or NF altered pediatric gliomas.
STARLITE for Unresectable High-Grade Gliomas
The purpose of this phase I study is to determine whether newly diagnosed high-grade glioma(s) that cannot be removed surgically change as a result of the study treatment (antiretrovirals and MRI-guided laser interstitial thermal therapy); and to identify and evaluate the potential side effects (good and bad) of the study treatment in patients with newly diagnosed high-grade glioma(s) that cannot be removed surgically.
Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
This phase I trial tests the safety, side effects, and best dose of anti-glycoprotein-A repetitions predominant (GARP) chimeric antigen receptor (CAR) T cell therapy and how well it works in treating patients with grade III or IV gliomas that have come back after a period of improvement (recurrent).
Digoxin Medulloblastoma Study
The purpose of this phase II study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.
IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Pediatric High-grade Glioma (HGG) (IMPACT)
This is a phase I study to assess the safety and feasibility of IL-8 receptor modified patient-derived activated CD70 CAR T cell therapy in CD70+ pediatric high-grade glioma.
CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy
This is a phase 1 study to assess the safety, feasibility, pharmacokinetics and preliminary efficacy of autologous T cells co-expressing two CARs targeting the cryptic EGFR epitope 806 and IL3Ra2 (referred to as “CART-EGFR-IL13Ra2 cells”) in patients with newly diagnosed, EGFR-amplified, MGMT-unmethylated glioblastoma who have undergone maximal safe surgical resection.
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent).
CUE-102 in Recurrent Glioblastoma
This is a phase Ib trial evaluating the safety and tolerability of CUE-102 (a fusion protein) in adult participants with glioblastoma (GBM) at first recurrence. CUE-102 is designed to target tumor cells by activating T cells, potentially improving clinical outcomes in recurrent GBM.
Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High-Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma
This phase I clinical trial studies the side effects and best dose of AZD1390 and to see how well it works when given together with radiation therapy for the treatment of pediatric patients with high-grade glioma, diffuse midline glioma, or diffuse intrinsic pontine glioma (DIPG).
Abemaciclib in Newly Diagnosed Meningioma Patients
This phase II study is being done to learn about how an investigational drug called abemaciclib works in treating patients with a newly-diagnosed grade 3 meningioma. Abemaciclib is a drug that is approved by the FDA, but not for brain tumors.
Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma (SRS-AIM)
This clinical trial tests the safety and effectiveness of hypofractionated stereotactic radiosurgery for treating patients who have undergone surgical resection for grade II meningiomas or grade I meningiomas that have come back after a period of improvement (recurrent).
Feasibility of CSF and Plasma ctDNA in BRAF-altered Glioma During Treatment With Plixorafenib
This clinical trial is designed as a pilot, signal-finding study to demonstrate the feasibility of detecting ctDNA at baseline and over time in response to treatment with plixorafenib co-administered with cobicistat in BRAF-V600E mutant glioma refractory to prior therapies.
Concurrent Azeliragon With Craniospinal Irradiation
This is a phase Ib study to assess the safety of concurrent Azeliragon with craniospinal irradiation (CSI) in patients with leptomeningeal metastasis from solid tumor malignancies and high-grade gliomas.
